(PharmaNewsWire.Com, July 13, 2017 ) Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type. It is estimated that around 75% of the patients suffering from hemophilia do not receive adequate treatment.
Latin America Hemophilia market is driven by factors such as growing prevalence of the disease and increasing usage of recombinant product. Advancements in technology have brought novel oagulating factors which are also helping in the growth of the market. Rising investments into Research and developments is also a major factor supporting the market growth. However lack of awareness of the disease and high costs associated with the treatment of the disease are the major factors hindering the market growth. Advancements in gene therapy and approaching approval of drugs for treatment of hemophilia provide immense growth opportunities in the market.
Latin America market for Hemophilia management is analyzed on the basis of type of hemophilia and drug. By type it is further segmented into Hemophilia A and Hemophilia B. On the basis of drug it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A the largest segment accounting for approximately XX% and is also estimated to be the fastest growing segment due to a large number of people suffering from the disease Hemophilia
On the basis of geography Latin America hemophilia management market is analyzed under various regions namely Brazil, Argentina and Mexico. Latin America region provides lucrative growth opportunities for the haemophilia management market attributed to local government support and increasing focus of global players towards these countries. Within Latin America, Argentina is a major market accounting for a significant share within the region due to more open investment prospects
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
